Loading...
Studies suggest that tirzepatide results in more weight loss than do the glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., NEJM JW Gen Med Aug 1 2021 and N Engl J Med 2021; 385:503). In a new retrospective cohort study, researchers used administrative databases to compare the relative effects of the two drug classes on cardiovascular and kidney diseases. About 140,000 patients with type 2 diabetes who recently initiated one of the two drugs were evaluated. Patients with severe chronic kidney disease or recent cardiovascular events were excluded.
Adjusted analyses showed that during a median follow-up of ≈1 year, tirzepatide was associated with significantly lower risk for all-cause mortality (hazard ratio, 0.58), major adverse cardiov…